MARKET

IDYA

IDYA

Ideaya Biosciences
NASDAQ
33.73
-0.08
-0.24%
Pre Market: 33.99 +0.26 +0.77% 05:44 12/18 EST
OPEN
33.70
PREV CLOSE
33.81
HIGH
34.16
LOW
33.42
VOLUME
39
TURNOVER
0
52 WEEK HIGH
37.08
52 WEEK LOW
13.45
MARKET CAP
2.96B
P/E (TTM)
-18.1872
1D
5D
1M
3M
1Y
5Y
1D
How Investors May Respond To IDEAYA Biosciences (IDYA) Regaining Oncology Programs After GSK Collaboration Exit
Simply Wall St · 15h ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 2d ago
IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress
Simply Wall St · 2d ago
Weekly Report: what happened at IDYA last week (1208-1212)?
Weekly Report · 3d ago
Ideaya Biosciences Advances with IDE892 Study Targeting MTAP-Deleted Tumors
TipRanks · 4d ago
IDEAYA Biosciences Faces Collaboration Termination by GSK
TipRanks · 5d ago
Citi places Ideaya on ‘upside 90-day catalyst watch’ into data
TipRanks · 6d ago
Promising Outlook for IDEAYA Biosciences: Buy Rating Backed by Positive Trial Expectations
TipRanks · 6d ago
More
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Webull offers Ideaya Biosciences Inc stock information, including NASDAQ: IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.